🔍

SANOFI - Sanofi India

📊 NSE: SANOFI 🏢 Pharmaceuticals - Multinational 📅 Last Updated: 12/14/2025 12:48

📢 Recent Corporate Announcements

Sanofi India Declares ₹48 Final Dividend and Appoints Rahul Bhatnagar as New Chairman

🟢 POSITIVE ⭐ 7/10

BOARD_MEETING 📅 29 Apr 2026, 08:33 PM

Sanofi India concluded its 70th Annual General Meeting on April 29, 2026, where shareholders approved a final dividend of ₹48 per equity share, bringing the total dividend for FY 2025 to ₹123 per share. A significant leadership transition was announced, with Rahul Bhatnagar succeeding Aditya Narayan as Chairman effective April 30, 2026. The meeting also saw the appointment of Sudipta Chakraborty as Whole-time Director and the approval of material related party transactions with Sanofi-Aventis Singapore and Sanofi Healthcare India. The company reported no qualifications in its statutory audit for the financial year ended December 31, 2025.

Confirmed total dividend of ₹123 per share for FY 2025, including a ₹75 interim and ₹48 final dividend.
Rahul Bhatnagar to take over as Chairman of the Board effective April 30, 2026.
Approved appointment of Ms. Sudipta Chakraborty as Whole-time Director and two new Independent Directors.
Ratified material related party transactions with Sanofi-Aventis Singapore Pte. Limited and Sanofi Healthcare India Private Limited.
Adopted audited financial statements for the year ended December 31, 2025, with no adverse auditor remarks.

💡 Investors should view the high dividend payout and the smooth leadership transition as signs of stability and strong governance. The stock remains an attractive option for dividend-seeking investors following the confirmation of the ₹123 total payout for the year.

Sanofi India Shareholders Approve ₹123 Total Dividend and New Board Appointments at 70th AGM

🟢 POSITIVE ⭐ 7/10

ROUTINE 📅 29 Apr 2026, 08:19 PM

Sanofi India Limited's shareholders have approved all 11 resolutions at the 70th Annual General Meeting held on April 29, 2026. A key highlight is the approval of a ₹48 per share final dividend, which combined with the ₹75 interim dividend, brings the total payout for FY2025 to ₹123 per share. The meeting also confirmed the appointment of Sudipta Chakraborty as Whole-time Director and two new Independent Directors for five-year terms. Furthermore, material related-party transactions with Sanofi-Aventis Singapore were cleared by the members.

Final dividend of ₹48 per share approved, resulting in a total FY2025 payout of ₹123 per share.
Appointment of Sudipta Chakraborty as Whole-time Director passed with 99.92% majority.
Two Independent Directors, Rajani Kesari and Siraj Azmat Chaudhry, appointed for 5-year terms until 2031.
All resolutions, including the adoption of FY2025 financial statements and related-party transactions, passed with requisite majority.

💡 Investors should note the high total dividend payout of ₹123 per share for FY2025, which continues Sanofi's trend of strong shareholder returns. The successful board appointments ensure governance stability and leadership continuity.

Sanofi India Appoints Rahul Bhatnagar as Chairman; Q1 Net Profit at ₹1,026 Million

🟡 NEUTRAL ⭐ 7/10

BOARD_MEETING 📅 28 Apr 2026, 07:04 PM

Sanofi India has appointed Mr. Rahul Bhatnagar as the new Chairman of the Board effective April 30, 2026, following the completion of tenure for two independent directors. For the quarter ended March 31, 2026, the company reported a revenue of ₹4,723 million, a decline from ₹5,359 million in the same period last year. Net profit also saw a decrease to ₹1,026 million from ₹1,195 million YoY, primarily due to partnership transitions. However, the core insulin portfolio remains a bright spot, delivering a strong 19% year-on-year growth.

Mr. Rahul Bhatnagar appointed as Chairman of the Board effective April 30, 2026.
Q1 2026 revenue from operations stood at ₹4,723 million, down 11.8% from ₹5,359 million in Q1 2025.
Net profit for the quarter decreased to ₹1,026 million compared to ₹1,195 million in the previous year.
Insulin portfolio achieved double-digit growth of 19% YoY and 14% sequentially.
Tenure of Independent Directors Mr. Aditya Narayan and Mrs. Usha Thorat ends on April 29, 2026.

💡 Investors should watch for the stabilization of partnership transitions which impacted this quarter's revenue. The continued double-digit growth in the insulin segment suggests strong market positioning in core therapeutic areas.

Sanofi India Q1 PAT at ₹1,026M; Rahul Bhatnagar Appointed Chairman as Insulin Sales Grow 19% YoY

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 28 Apr 2026, 06:51 PM

Sanofi India reported a Profit After Tax of ₹1,026 million for the quarter ended March 31, 2026, showing a strong sequential recovery from the previous quarter's ₹617 million. While revenue of ₹4,723 million was lower than the same period last year (₹5,359 million), the company's core insulin portfolio showed significant momentum with 19% year-on-year growth. The board also underwent a leadership transition, appointing Rahul Bhatnagar as the new Chairman effective April 30, 2026. Management noted that while partnership transitions impacted overall quarterly results, export sales are beginning to stabilize.

Net Profit for Q1 2026 stood at ₹1,026 million, representing a 66% sequential increase from Q4 2025.
Revenue from operations reached ₹4,723 million, a decline of 11.8% compared to ₹5,359 million in Q1 2025.
The Insulin portfolio delivered exceptional performance with 19% YoY and 14% QoQ growth.
Rahul Bhatnagar appointed as Chairman of the Board effective April 30, 2026, following the completion of tenures of two independent directors.
Basic and diluted Earnings Per Share (EPS) for the quarter was ₹44.55, down from ₹51.89 in the previous year's quarter.

💡 Investors should monitor the impact of ongoing partnership transitions on revenue and margins, while keeping a close eye on the continued growth of the high-margin insulin segment. The leadership change appears to be a planned transition, but the year-on-year decline in top-line performance requires a cautious outlook.

Sanofi India Q1 Net Profit Dips 14% YoY to ₹1,026 Mn; Insulin Portfolio Grows 19%

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 28 Apr 2026, 06:44 PM

Sanofi India reported a 14% year-on-year decline in net profit to ₹1,026 million for the quarter ended March 31, 2026, as revenue was impacted by partnership transitions. Revenue from operations fell 11.8% YoY to ₹4,723 million, though it showed a healthy sequential recovery of 12.5% compared to the previous quarter. The company's core insulin portfolio remains a standout performer, registering 19% YoY growth and 14% QoQ growth. The board also announced leadership changes, appointing Rahul Bhatnagar as the new Chairman effective April 30, 2026.

Net Profit for the quarter stood at ₹1,026 million, down 14.1% compared to ₹1,195 million in the previous year's corresponding quarter.
Revenue from operations decreased to ₹4,723 million from ₹5,359 million YoY, primarily due to transactions relating to partnership transitions.
The Insulin portfolio delivered robust growth of 19% YoY and 14% QoQ, demonstrating strong equity in the diabetes segment.
Profit before tax (PBT) showed a significant sequential improvement, rising 66% from ₹830 million in Q4 2025 to ₹1,379 million.
Mr. Rahul Bhatnagar has been appointed as the Chairman of the Board effective April 30, 2026, following the completion of tenures of two independent directors.

💡 Investors should focus on the strong sequential recovery and the resilience of the insulin portfolio despite the temporary impact of partnership transitions. The leadership change and committee reconstitutions suggest a period of governance transition alongside business model adjustments.

Sanofi India Q1 PAT Drops 14% YoY to ₹103 Cr; Rahul Bhatnagar Appointed Chairman

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 28 Apr 2026, 06:36 PM

Sanofi India reported a 14.1% YoY decline in Net Profit to ₹1,026 million for the quarter ended March 31, 2026, while revenue fell 11.9% YoY to ₹4,723 million. The performance was primarily impacted by transitions in business partnerships, though the core insulin portfolio showed strong resilience with 19% YoY growth. Sequentially, the company demonstrated a sharp recovery with PAT rising 66.3% compared to the December 2025 quarter. Additionally, the board has appointed Rahul Bhatnagar as the new Chairman effective April 30, 2026.

Revenue from operations decreased 11.9% YoY to ₹4,723 million from ₹5,359 million.
Net Profit (PAT) stood at ₹1,026 million, down 14.1% YoY but up 66.3% on a QoQ basis.
Insulin portfolio delivered robust growth of 19% YoY and 14% over the previous quarter.
Rahul Bhatnagar appointed as Chairman of the Board following the completion of tenure of previous directors.
Earnings Per Share (EPS) for the quarter was ₹44.55, down from ₹51.89 in the same period last year.

💡 Investors should monitor the stabilization of partnership transitions which impacted top-line growth this quarter. The strong sequential recovery and leadership change suggest a period of consolidation; long-term holders should focus on the insulin portfolio's continued dominance.

Sanofi India Receives ₹52.08 Lakh GST Refund Order; to Appeal Rejected Claim of ₹11.63 Lakh

🟢 POSITIVE ⭐ 3/10

REGULATORY 📅 21 Apr 2026, 06:33 PM

Sanofi India Limited has received a refund order from the Assistant Commissioner of CGST, Vadodara, for the period August 2014 to June 2017. The authority has granted a total refund of ₹52.08 lakh, which includes a principal amount of ₹33.97 lakh and interest of ₹18.11 lakh. This refund pertains to pre-deposits made during an appeal process that was successfully decided in the company's favor. However, the authority rejected a portion of the claim amounting to ₹11.63 lakh, for which the company intends to file a further appeal.

Total refund of ₹52,07,841 granted by CGST authorities for the period 2014-2017.
Refund comprises ₹33,96,705 in principal and ₹18,11,136 in interest.
The claim relates to pre-deposits for an appeal where the final decision was in favor of Sanofi India.
Company to appeal against the non-grant of the remaining refund balance of ₹11,62,853.

💡 This is a minor regulatory update with negligible impact on the company's overall financial health. No immediate action is required as the refund amount is small relative to the company's scale.

Sanofi India Submits Quarterly SEBI Compliance Certificate for March 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Apr 2026, 09:47 PM

Sanofi India Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, provided by Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited, covers the period from January 1, 2026, to March 31, 2026. It confirms that all share certificates received for dematerialization were processed, mutilated, and cancelled according to regulatory standards. The filing ensures that the company's shareholding records are accurately maintained with the depositories.

Compliance certificate issued for the quarter ended March 31, 2026
Confirmation provided by RTA MUFG Intime India Private Limited
Securities received for dematerialization were listed on relevant stock exchanges
Verification and cancellation of physical certificates completed within prescribed timelines
Register of members updated with depository names as registered owners

💡 No action is required from investors as this is a standard administrative filing confirming regulatory compliance regarding share processing.

Sanofi India Announces 70th AGM and Final Dividend of Rs. 48 Per Share

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 02 Apr 2026, 08:08 PM

Sanofi India Limited has scheduled its 70th Annual General Meeting (AGM) for April 29, 2026, to discuss the financial year ended December 31, 2025. The company has recommended a final dividend of Rs. 48 per share, with the record date set for April 22, 2026. Shareholders must update their KYC and bank details by April 15, 2026, to ensure seamless dividend credit. Additionally, a special regulatory window is open until February 2027 for the dematerialization of physical shares held before April 2019.

Final dividend of Rs. 48 per share announced for the financial year ended December 31, 2025
Record date for dividend eligibility and e-voting cut-off is April 22, 2026
70th Annual General Meeting scheduled for April 29, 2026, via Video Conferencing
Dividend payment to be completed on or before May 28, 2026
Special one-year window (Feb 2026 - Feb 2027) for transfer and demat of old physical securities

💡 Investors should ensure they hold shares by the record date of April 22, 2026, to qualify for the Rs. 48 dividend. Physical shareholders should utilize the special window to dematerialize their holdings before February 2027.

Sanofi India Announces Rs 48 Final Dividend; Sets Record Date for April 22, 2026

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 02 Apr 2026, 08:04 PM

Sanofi India has recommended a final dividend of Rs 48 per equity share for the financial year ended December 31, 2025. The company has fixed April 22, 2026, as the record date to determine shareholder eligibility for this payout. Investors are required to submit tax-related declarations by April 15, 2026, to ensure the correct Tax Deduction at Source (TDS) rate is applied. Additionally, the company has transitioned to exclusively electronic payment modes, discontinuing physical dividend warrants.

Final dividend of Rs 48 per equity share recommended for the financial year ended December 31, 2025.
Record date for dividend eligibility is April 22, 2026, with a document submission deadline of April 15, 2026.
Standard TDS of 10% applies to resident individuals with valid PAN, while 20% applies if PAN is missing.
No TDS will be deducted for resident individual shareholders if the total dividend does not exceed Rs 10,000.
Physical dividend warrants are discontinued; all payments will be made via electronic modes like NEFT/RTGS.

💡 Shareholders should ensure their PAN and bank account details are updated with their Depository Participant or RTA before the record date. Eligible investors should submit Form 15G/15H or DTAA documents by April 15 to minimize tax withholding.

Sanofi India Receives Govt Approval for Deepak Arora as Managing Director for 3-Year Term

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 02 Apr 2026, 07:59 PM

Sanofi India Limited has received formal approval from the Central Government for the appointment of Mr. Deepak Arora as the Managing Director. The appointment is valid for a period of 3 years, effective retrospectively from October 27, 2025. This regulatory clearance follows the company's initial board intimations made in October and December 2025. The approval ensures leadership continuity and fulfills statutory requirements for the top executive position.

Central Government approval received on April 1, 2026, for the appointment of Mr. Deepak Arora.
The appointment as Managing Director is for a fixed tenure of 3 years.
The term is effective from October 27, 2025, providing retrospective leadership validation.
The approval concludes a regulatory process initiated via board resolutions in late 2025.

💡 Investors should view this as a positive administrative milestone that ensures leadership stability. No immediate action is required as the appointment was previously anticipated and is now formally ratified.

Sanofi India Receives Income Tax Demand of ₹12.37 Crore for FY 2022-23

🔴 NEGATIVE ⭐ 4/10

LEGAL 📅 28 Mar 2026, 03:51 PM

Sanofi India Limited has received a final assessment order from the Income Tax Department for the financial year 2022-23 (AY 2023-24). The order demands a total tax liability of ₹12,36,99,710, which includes interest. The primary reasons for the demand are adjustments related to transfer pricing and the disallowance of payments made to healthcare professionals. The company has stated its intention to appeal this order before higher tax authorities to contest the adjustments.

Final assessment order received for FY 2022-23 (AY 2023-24) on March 27, 2026
Total tax liability determined at INR 12,36,99,710 including interest
Demand stems from transfer pricing issues and disallowed payments to healthcare professionals
Company to file an appeal with higher tax authorities against the assessment order

💡 Investors should note this as a routine tax dispute; while the ₹12.37 crore demand is negative, it is not materially significant relative to the company's overall financials. Monitor the outcome of the appeal process for any potential impact on future tax provisions.

Sanofi India Sets Record Date for ₹48 Final Dividend; Appoints Siraj Chaudhry to Board

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 25 Mar 2026, 01:07 PM

Sanofi India has announced April 22, 2026, as the record date for its final dividend of ₹48 per equity share for the financial year ended December 31, 2025. The company will hold its 70th Annual General Meeting on April 29, 2026, to seek shareholder approval for this payout. Additionally, the board has appointed Siraj Azmat Chaudhry, former Chairman of Cargill India, as an Independent Director for a five-year term. This leadership addition brings significant FMCG and agricultural sector expertise to the board.

Final dividend of ₹48 per equity share (face value ₹10) recommended for FY ended Dec 31, 2025.
Record date for dividend eligibility fixed as April 22, 2026; Book closure from April 23 to April 29, 2026.
Appointment of Siraj Azmat Chaudhry as Independent Director for a 5-year term starting April 1, 2026.
70th Annual General Meeting scheduled for April 29, 2026, via Video Conferencing.
Mr. Chaudhry brings over 35 years of experience, including leadership roles at Cargill India and various industry bodies.

💡 Investors interested in the ₹48 dividend should ensure they hold the stock before the ex-dividend date (typically one day prior to the April 22 record date). The high-profile board appointment is a positive signal for the company's governance and strategic oversight.

Sanofi India Sets April 22 as Record Date for ₹48 Final Dividend; Appoints New Director

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 25 Mar 2026, 12:51 PM

Sanofi India has finalized April 22, 2026, as the record date for its final dividend of ₹48 per equity share for the financial year ended December 31, 2025. The dividend payment is subject to shareholder approval at the 70th Annual General Meeting (AGM) scheduled for April 29, 2026. In a significant management update, the company has also appointed Mr. Siraj Azmat Chaudhry, former Chairman of Cargill India, as an Independent Director for a five-year term. The book closure for the dividend and AGM will occur from April 23 to April 29, 2026.

Final dividend of ₹48 per equity share of face value ₹10 recommended for FY2025.
Record date for dividend eligibility fixed as April 22, 2026.
70th Annual General Meeting (AGM) to be held on April 29, 2026.
Appointment of Mr. Siraj Azmat Chaudhry as Independent Director for a 5-year term starting April 1, 2026.
Book closure period for dividend and AGM set from April 23 to April 29, 2026.

💡 Investors looking to benefit from the ₹48 dividend should ensure they hold the stock before the ex-dividend date (typically one day prior to the April 22 record date). The addition of an experienced industry leader like Siraj Chaudhry to the board is a positive governance signal.

Sanofi India Sets Record Date for ₹48 Dividend and Appoints New Independent Director

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 25 Mar 2026, 12:49 PM

Sanofi India has scheduled its 70th Annual General Meeting for April 29, 2026, to seek shareholder approval for various resolutions. The company has fixed April 22, 2026, as the record date for the final dividend of ₹48 per equity share for the financial year ended December 31, 2025. Furthermore, the board has appointed Mr. Siraj Azmat Chaudhry, former Chairman of Cargill India, as an Independent Director for a five-year term. These announcements provide clarity on the dividend payout timeline and demonstrate a strengthening of the company's governance framework.

Final dividend of ₹48 per equity share of ₹10 each recommended for the year ended Dec 31, 2025.
Record date for dividend eligibility is fixed as Wednesday, April 22, 2026.
70th Annual General Meeting (AGM) scheduled for April 29, 2026, at 3:30 p.m. IST.
Appointment of Mr. Siraj Azmat Chaudhry as Independent Director for a 5-year term starting April 1, 2026.
Mr. Chaudhry brings 35 years of experience, including leading Cargill India to a ₹5,000 crore entity.

💡 Investors interested in the ₹48 per share dividend should ensure they hold the stock by the record date of April 22, 2026. The appointment of a high-profile industry veteran to the board is a positive sign for long-term strategic oversight.

View All SANOFI Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The core business (Diabetes insulin, Cardiovascular, CNS, and Oral Anti-diabetes) grew 4% YTD September 2025 and 5% on a quarter-to-quarter basis. Partnership-led revenue grew 2% YTD and 5% quarter-to-quarter.

Geographic Revenue Split

Not disclosed in available documents; however, operations are primarily focused on the Indian market through Sanofi India Limited.

Profitability Margins

Operating margins were reported at approximately 28% for the current quarter, driven by optimization and efficiency measures.

EBITDA Margin

Operating margins of 28% reflect core profitability; the company is actively pursuing optimization to enhance these levels further from the current 28% baseline.

⚙️ Operational Drivers

Key Suppliers

Emcure Pharmaceuticals is a key strategic partner for the distribution and potentially the supply chain of oral anti-diabetes products.

Manufacturing Efficiency

AI-driven forecasting has reached an accuracy level of +/- 1% compared to reality, significantly improving supply chain planning and reducing waste.

📈 Strategic Growth

Expected Growth Rate

Growth Strategy

Growth is driven by a 'pivotal transformation' in 2025 involving strategic partnerships like the one with Emcure for oral anti-diabetes. The company is also focusing on new product launches such as Soliqua and expanding the 'share of voice' for glargine products (Lantus and Toujeo). Cost optimization, including a reduction in personnel costs from INR 56 Cr to INR 42 Cr (a 25% decrease) via VRS, is intended to protect margins.

Products & Services

Insulin cartridges, DispoPens, oral anti-diabetes medications, cardiovascular drugs, and CNS (Central Nervous System) therapies.

Brand Portfolio

Lantus, Toujeo, Soliqua.

New Products/Services

Launch of Soliqua and assessment of Type 1 Diabetes (T1D) innovations for the Indian market.

Market Expansion

Targeting the human insulin cartridges and DispoPen market, which has an estimated size of INR 450 Cr to INR 500 Cr, following the exit of a major competitor (Novo Nordisk).

Strategic Alliances

Partnership with Emcure Pharmaceuticals for the oral anti-diabetes segment announced in July 2025.

🌍 External Factors

Industry Trends

The industry is shifting toward biosimilars to improve the 'share of voice' for glargine in the marketplace. Sanofi is positioning itself by innovating in the T1D segment and adopting AI for operational forecasting and regulatory affairs.

Competitive Landscape

Key dynamics include the exit of Novo Nordisk from the human insulin cartridge and DispoPen market, creating a significant vacuum for Sanofi to fill.

Competitive Moat

The company maintains a strong competitive position in the insulin market (Lantus/Toujeo) and is capitalizing on competitor exits in the human insulin cartridge segment (INR 450-500 Cr market size). Sustainability is bolstered by a global commitment to net-zero emissions by 2045.

Macro Economic Sensitivity

Sensitive to changes in the regulatory environment and geopolitical stability which can impact the timeline for achieving corporate goals.

Consumer Behavior

Increased demand for advanced insulin delivery systems like cartridges and pens over traditional methods.

Geopolitical Risks

Geopolitical stability is cited as a significant uncertainty that could prevent the company from achieving its specified metrics or targets.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to complex regulatory requirements and health and safety standards; 100% of plants and offices are assessed for compliance.

Environmental Compliance

Committed to 100% renewable electricity by 2030 and zero landfill status as part of environmental responsibility initiatives.

⚠️ Risk Analysis

Key Uncertainties

Significant uncertainties inherent in forward-looking statements regarding the achievement of goals within specified timeframes due to regulatory and cost fluctuations.